NASDAQ:DYN - US26818M1080 - Common Stock
The current stock price of DYN is 13.49 USD. In the past month the price increased by 34.23%. In the past year, price decreased by -70.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.87 | 371.68B | ||
AMGN | AMGEN INC | 13.19 | 154.89B | ||
GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
INSM | INSMED INC | N/A | 28.77B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
NTRA | NATERA INC | N/A | 23.09B | ||
BIIB | BIOGEN INC | 8.26 | 19.38B |
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 206 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
DYNE THERAPEUTICS INC
1560 Trapelo Road
Waltham MASSACHUSETTS 02451 US
CEO: Joshua Brumm
Employees: 206
Phone: 17817868230
The current stock price of DYN is 13.49 USD. The price decreased by -1.89% in the last trading session.
The exchange symbol of DYNE THERAPEUTICS INC is DYN and it is listed on the Nasdaq exchange.
DYN stock is listed on the Nasdaq exchange.
21 analysts have analysed DYN and the average price target is 36.55 USD. This implies a price increase of 170.94% is expected in the next year compared to the current price of 13.49. Check the DYNE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
DYNE THERAPEUTICS INC (DYN) has a market capitalization of 1.92B USD. This makes DYN a Small Cap stock.
DYNE THERAPEUTICS INC (DYN) currently has 206 employees.
DYNE THERAPEUTICS INC (DYN) has a support level at 13.18 and a resistance level at 14.71. Check the full technical report for a detailed analysis of DYN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
DYN does not pay a dividend.
DYNE THERAPEUTICS INC (DYN) will report earnings on 2025-11-10, after the market close.
DYNE THERAPEUTICS INC (DYN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.86).
The outstanding short interest for DYNE THERAPEUTICS INC (DYN) is 12.33% of its float. Check the ownership tab for more information on the DYN short interest.
ChartMill assigns a technical rating of 6 / 10 to DYN. When comparing the yearly performance of all stocks, DYN is a bad performer in the overall market: 92.78% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to DYN. The financial health of DYN is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months DYN reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS decreased by -7.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -56.64% | ||
ROE | -72.25% | ||
Debt/Equity | 0.17 |
21 analysts have analysed DYN and the average price target is 36.55 USD. This implies a price increase of 170.94% is expected in the next year compared to the current price of 13.49.